DICER1 and glioblastoma: Their unscheduled accumulation has emerged as a promising diagnostic biomarker, with the potential to stratify patients and monitor disease severity across various conditions, including immune deficiencies like Wiskott–Aldrich syndrome [106], leukemia [72], embryonal tumors with correlation to loss of DICER1 function [107], and glioblastomas [108], also in correlation with DICER1 expression [109, 110, 111].